Searched for
CIPLA MERGER
Cipla faces revenue and margin pressure ahead of Revlimid patent expiryCipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst downgrades. Mar...- Stocks in news: ZEE, Cipla, Axis Bank, IndiGo, Kotak Bank, ICICI Bank, Persistent SystemsInterGlobe Enterprises, which runs and operates IndiGo airline, appointed Aditya Pande as the Group CEO with effect from March 2024.
- Cipla stake sale plan faces hurdle as promoters differ on valuation: ReportCipla's potential stake sale faces a challenge due to disagreements among its promoters regarding the company's valuation. This dispute amo...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- Medley-Cipla deal talks called off over valuation issuesThis is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility ...
- Ananth Narayanan is Medlife CEOThe move comes at a time when Medlife is in the midst of a $150 million fundraising round from strategic as well as institutional investors.
- India Inc's Jan-Nov M&A deal tally at $82 billion: ReportIn November 2017, there were 39 deals worth USD 3.2 billion.
- Cadila Healthcare, Torrent Pharma eyeing potential merger"More clarity on the proposed structure, valuations can be expected in the next six months," a source said adding that the merger may or ma...
- CLSA increases underweight on Infosys in model portfolioInfosys had lowered its dollar revenue guidance to 10.5-12% in constant currency terms from its earlier forecast of 11.5-13.5% in July.
- DRL, Cipla, Aurobindo among others to buy products from TevaThe remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...
- Prefer pharma to IT stocks; positive on Cipla, Lupin: Deepak ShenoyGiven the rupee, where it is right now, the September quarter numbers will be pretty good for pharma companies, says Shenoy.
- Sensex ends in red, Nestle surprise winner, up over 9% in late trade, Cairn top loser17 of 30 Sensex stocks ended the day in red. Vedanta Ltd was the gainer on Sensex, up over 2%. Cairn India was the top loser on NSE Nifty, ...
- Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel BrokingI believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance f...
- Dr Reddy's, Sun Pharma stand out in the pharma sector: Mayuresh Joshi"The valuations are little bit on the higher side. Clearly the growth trajectory is there for the companies and an addressable market size ...
- Need continuity in policies for pharma sector: YK Hamied, CiplaNow if you look at the world’s top 70 drugs, 50% of them or more are made and marketed by companies that did not invent them.
- Pharma companies on a talent hunt to fill skills gapThe sector has slowed from its peak growth rate, the lure of expansion in the Rs 75,000-crore pharma market has kept companies looking for ...
- Bullish about pharma space: Sonam UdasiIn a chat with ET Now, Sonam Udasi, Head of Research, IDBI Capital, shares his views on pharma sector.
- India Inc's 9-mth M&A deal tally at $24 bn: Grant ThorntonIndian M&A market showed moderate levels of deal activity in the first nine months of this year with 377 deals amounting to $23.9 billion.
- Pharma M&As set to gather more steam in 2013: Report'Besides inorganic initiatives, the industry is also stepping up its organic investments.'
- Cipla plans Rs 2,000-crore capex by FY 10Pharmaceuticals major Cipla Ltd has drawn up a Rs 2,000-crore capex plan over the next two years, a top company official said on Thursday.
Load More
